VANCOUVER, Sept. 11, 2012 /CNW/ - Allon Therapeutics Inc. (TSX: NPC) President and CEO Gordon McCauley will present an update of the Company's business progress on Tuesday,
September 11 at the Rodman and Renshaw Annual Global Investment Conference in New York City.
McCauley's presentation will include an update of the Company's
programs, including its pivotal Phase 2/3 clinical trial evaluating
lead neuroprotective drug candidate, davunetide, as a potential treatment for progressive supranuclear palsy (PSP), a rapidly progressing and fatal degenerative brain disease.
The fully enrolled pivotal trial is proceeding under a Special Protocol
Assessment with the U.S. Food and Drug Administration and is expected
to complete patient dosing and release top-line data in Q4 2012. It is
being conducted at leading medical institutions in the United States,
Canada, the United Kingdom, France, Germany, and Australia. Details can
be found at clinical trials.gov.
The live webcast may be viewed at 12:40 p.m. PDT (3:40 p.m. EDT) at http://www.wsw.com/webcast/rrshq22/npc.cn. The presentation will be immediately archived and available for
viewing for three months from the Company's website at http://www.allontherapeutics.com/corporate/news/events-and-webcasts/.
Rodman & Renshaw is a full-service investment bank dedicated to
providing corporate finance, strategic advisory and related services to
public and private companies across multiple sectors and regions.
Rodman also provides research and sales and trading services to
Allon Therapeutics Inc. is a clinical-stage biotechnology company
focused on bringing to market innovative central nervous system
therapies. Allon's lead drug davunetide is proceeding in a pivotal clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the U.S. Food and
Drug Administration (FDA). The trial is fully enrolled and on track to
complete the study, analyse the data and release top-line results
before the end of 2012. This pivotal trial is based upon statistically
significant human efficacy demonstrated in patients with amnestic mild
cognitive impairment, cognitive impairment associated with
schizophrenia, and in positive biomarker data.
The Company is listed on the Toronto Stock Exchange under the trading
Forward Looking Statements
Statements contained herein, other than those which are strictly
statements of historical fact may include forward-looking information.
Such statements will typically contain words such as "believes", "may",
"plans", "will", "estimate", "continue", "anticipates", "intends",
"expects", and similar expressions. While forward-looking statements
represent management's outlook based on assumptions that management
believes are reasonable, forward-looking statements by their nature are
subject to known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be
materially different from any future results, events or developments
expressed or implied by them. Such factors include, among others, the
inherent uncertainty involved in scientific research and drug
development, Allon's early stage of development, lack of product
revenues, its additional capital requirements, the risks associated
with successful completion of clinical trials and the long lead-times
and high costs associated with obtaining regulatory approval to market
any product which Allon may eventually develop. Other risk factors
include the limited protections afforded by intellectual property
rights, rapid technology and product obsolescence in a highly
competitive environment and Allon's dependence on collaborative
partners and contract research organizations. These factors can be
reviewed in Allon's public filings at www.sedar.com and should be considered carefully. Readers are cautioned not to place
undue reliance on such forward-looking statements. Similarly, nothing
in this press release is meant to promote a pharmaceutical product or
make a regulated claim of efficacy.
SOURCE: Allon Therapeutics Inc.
For further information: